Sorrento Therapeutics IncOver The Counter Market:SRNE
- LAST PRICE0.0200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0130 / 0.0200
- Day Range
- 52 Week Range
- Volume62,408
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SRNE |
|---|---|---|
| 09:32 ET | 40000 | 0.013 |
| 09:39 ET | 2796 | 0.013 |
| 09:54 ET | 100 | 0.02 |
| 10:28 ET | 399 | 0.02 |
| 10:32 ET | 556 | 0.02 |
| 10:37 ET | 2000 | 0.02 |
| 11:06 ET | 850 | 0.02 |
| 12:02 ET | 1137 | 0.02 |
| 12:12 ET | 340 | 0.02 |
| 12:50 ET | 100 | 0.02 |
| 01:14 ET | 300 | 0.02 |
| 01:48 ET | 300 | 0.02 |
| 01:53 ET | 8000 | 0.02 |
| 02:04 ET | 150 | 0.02 |
| 02:29 ET | 4600 | 0.02 |
| 02:42 ET | 129 | 0.02 |
| 02:44 ET | 400 | 0.02 |
Mar 27, 2024
*DJ Scilex Holding Says U.S. Bankruptcy Court Extended Lockup Period on Shares Previously Distributed by Sorrento to Its Stockholders as a Dividend >SCLX, from 9:01AM ET on Wednesday Mar 27, 2024 by Dow Jones
9:01AM ET on Wednesday Mar 27, 2024 by Dow JonesScilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend, from 9:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
9:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sorrento Therapeutics Inc | 11.0M | 0.0x | --- |
Molecular Templates Inc | 10.8M | -1.0x | --- |
Cidara Therapeutics Inc | 56.1M | -51.4x | --- |
Centogene NV | 12.8M | -0.3x | --- |
Bioqual Inc | 67.1M | -146.6x | -25.28% |
Neptune Wellness Solutions Inc | 226.6K | 0.0x | --- |
Company Information
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
Contact Information
- Headquarters
- 4955 Directors PlaceSAN DIEGO, CA, United States 92121
- Phone
- 858-203-4100
- Fax
- 858-203-4028
Executives
- Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
- Henry Ji
- Lead Independent Director
- Dorman Followwill
- Director
- Kim Janda
- Director
- Jaisim Shah
- Independent Director
- David Lemus
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.0M |
|---|---|
Revenue (TTM) | $64.3M |
Shares Outstanding | 551.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.84 |
EPS | $-1.09 |
Book Value | $-0.04 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -734.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
